Loading organizations...

§ Private Profile · Cambridge, MA, USA
Platelet BioGenesis is a technology company.
Platelet BioGenesis develops donor-independent, lab-manufactured human platelets, addressing a critical need for safe and readily available blood products. The company focuses on an ex vivo production process, generating functional platelets from induced pluripotent stem cells. This innovative approach aims to circumvent the limitations of traditional donor-derived platelets, offering a more consistent, sterile, and potentially longer-lasting therapeutic option for transfusion medicine.
The company emerged from the academic work of Dr. Jonathan Thon and Dr. Joseph Italiano, who spun Platelet BioGenesis out of their labs at Brigham and Women's Hospital and Harvard Medical School. Their foundational insight involved pioneering methods to produce viable megakaryocytes and platelets from stem cells outside the human body, recognizing the significant unmet demand for platelet transfusions globally.
Platelet BioGenesis targets a broad patient population requiring platelet transfusions, including oncology patients, those undergoing major surgery, and trauma victims. Its overarching vision centers on establishing a scalable and reliable supply of therapeutic platelets, ultimately striving to enhance patient outcomes by eliminating dependency on human donors and ensuring universal access to this life-saving blood component.
Platelet BioGenesis has raised $58.3M across 4 funding rounds.
Platelet BioGenesis has raised $58.3M in total across 4 funding rounds.
Platelet BioGenesis is a Cambridge, MA–based biotech company that develops a proprietary platform to produce human platelets at scale from pluripotent stem cells, targeting donor‑independent, on‑demand platelet supplies for transfusion and related therapeutic applications[1][4].
High-Level Overview
For a portfolio‑company framing (i.e., describing Platelet BioGenesis as the company in question):
Origin Story
Core Differentiators
Role in the Broader Tech Landscape
Quick Take & Future Outlook
Sources: Company profiles and industry reporting summarizing the firm’s platform, founding, funding and milestones[1][2][3][4][5][6].
Platelet BioGenesis has raised $58.3M in total across 4 funding rounds.
Platelet BioGenesis's investors include Christopher Herr, Kathy Zolman, Qiming Venture Partners USA, Steven M. Altschuler, eCoast Angels, Nest.Bio Ventures, Adena Partners, VI Ventures, Edgar G. Engleman.
Platelet BioGenesis has raised $58.3M across 4 funding rounds. Most recently, it raised $20.0M Debt in November 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 9, 2021 | $20M Debt Financing | Christopher Herr | — | Announced |
| Dec 16, 2019 | $2.3M Grant | Kathy Zolman | — | Announced |
| Sep 1, 2019 | $26M Series A | Qiming Venture Partners USA, Steven M. Altschuler | ECoast Angels, Nest.Bio Ventures | Announced |
| Jun 9, 2017 | $10M Series A | Qiming Venture Partners USA | Adena Partners, ECoast Angels, VI Ventures, Edgar G. Engleman | Announced |